Literature DB >> 22933209

An assessment of regression of left ventricular hypertrophy following alcohol ablation of the interventricular septum in patients with hypertrophic cardiomyopathy with left ventricular outflow tract obstruction.

Maciej Dąbrowski1, Lidia Chojnowska, Lukasz Małek, Mateusz Spiewak, Beata Kuśmierczyk, Jacek Koziarek, Anna Klisiewicz, Jolanta Miśko, Adam Witkowski.   

Abstract

BACKGROUND: Hypertrophic obstructive cardiomyopathy (HOCM) is characterised by asymmetric myocardial hypertrophy, which is most pronounced in the interventricular septum (IVS) and is responsible for the dynamic obstruction of the left ventricular outflow tract (LVOT). Successful alcohol septal ablation (ASA) of the IVS allows to reduce the thickness of the parabasal part of the IVS myocardium and, in most cases, to permanently reduce the gradient in the LVOT. AIM: To assess, using cardiac magnetic resonance imaging (MRI) and transthoracic echocardiography (TTE), the impact of gradient reduction in the LVOT on the type and severity of left ventricular (LV) remodelling.
METHODS: The study included 30 patients (aged 56.9 ± 11.9 years) with HOCM and the mean peak gradient (PG) in the LVOT of 123 ± 33 mm Hg who underwent ASA. MRI measurements were performed before and at 6 months after ASA and TTE measurements were performed before, at 3 months and at 6 months after ASA.
RESULTS: PG in the LVOT decreased to an average of 52 ± 37 mm Hg (p 〈 0.0001) at 3 months after ASA and to 37 ± 28 mm Hg (p 〈 0.0001) at 6 months after ASA. TTE revealed a decrease in IVS thickness outside the scar following ASA from 23.6 ± 3.5 mm to 19.3 ± 4.0 mm (p 〈 0.0001) and 19.4 ± 0.4 mm (p 〈 0.0001) at 3 and 6 months, respectively. There was also a decrease in lateral wall (PW) thickness from 15.9 ± 3.2 mm to 14.9 ± 2.9 mm (p = 0.046) and 14.16 ± 2.00 (p = 0.0065) at 3 and 6 months, respectively. MRI revealed a decrease in IVS thickness from 23.7 ± 2.8 mm to 18.04 ± 4.00 mm (p = 0.0001) at 6 months following ASA. We observed a regression of the PW hypertrophy from 13.2 ± 3.35 mm to 12.18 ± 2.4 mm (p = 0.0225). There was a decrease in IVS mass from 108.9 ± 20 g to 91.5 ± 29 g (p = 0.0006). There was a trend towards a decreased LV mass and LV mass excluding IVS mass at 6 months.
CONCLUSIONS: A significant decrease in PG in the LVOT is associated with a decrease in LV mass and with regression of LV hypertrophy outside the scar after ASA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22933209

Source DB:  PubMed          Journal:  Kardiol Pol        ISSN: 0022-9032            Impact factor:   3.108


  5 in total

1.  Maturation of Lesions Induced by Myocardial Cavitation-Enabled Therapy.

Authors:  Xiaofang Lu; Douglas L Miller; Chunyan Dou; Yiying I Zhu; Mario L Fabiilli; Gabe E Owens; Oliver D Kripfgans
Journal:  Ultrasound Med Biol       Date:  2016-04-14       Impact factor: 2.998

2.  Ultrasonic Cavitation-Enabled Treatment for Therapy of Hypertrophic Cardiomyopathy: Proof of Principle.

Authors:  Douglas L Miller; Xiaofang Lu; Chunyan Dou; Yiying I Zhu; Rachael Fuller; Kristina Fields; Mario L Fabiilli; Gabe E Owens; David Gordon; Oliver D Kripfgans
Journal:  Ultrasound Med Biol       Date:  2018-04-19       Impact factor: 2.998

3.  Comparison of mitral regurgitation severity assessments based on magnetic resonance imaging and echocardiography in patients with hypertrophic cardiomyopathy.

Authors:  Mateusz Śpiewak; Mariusz Kłopotowski; Ewa Kowalik; Łukasz Mazurkiewicz; Katarzyna Kożuch; Joanna Petryka-Mazurkiewicz; Barbara Miłosz-Wieczorek; Adam Witkowski; Anna Klisiewicz; Magdalena Marczak
Journal:  Sci Rep       Date:  2021-10-06       Impact factor: 4.379

Review 4.  Mitral valve replacement complicated by iatrogenic left ventricular outflow obstruction and paravalvular leak: case report and review of literature.

Authors:  Justin Z Lee; Kai R Tey; Ahmad Mizyed; Charles T Hennemeyer; Rajesh Janardhanan; Kapildeo Lotun
Journal:  BMC Cardiovasc Disord       Date:  2015-10-09       Impact factor: 2.298

5.  Multiple ultrasound cavitation-enabled treatments for myocardial reduction.

Authors:  Douglas L Miller; Xiaofang Lu; Chunyan Dou; Yiying I Zhu; Mario L Fabiilli; Gabe E Owens; Oliver D Kripfgans
Journal:  J Ther Ultrasound       Date:  2017-11-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.